Summit Therapeutics plc

Akeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes

Results from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi

BioNTech made its name and fortune with its Pfizer-partnered COVID-19 vaccine, Comirnaty, but this year could be a turning point in its bid to diversify and become a major oncology company as well. Th

Summit Therapeutics and its partner Akeso have a commanding lead in the VEGF x PD-(L)1 bispecific cancer immunotherapy field, but BioNTech is also focused on being a major contender. Several key clini